FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

REGISTER

now for free

Beth Thomas

Research Profile

Chemicals & Drugs

Concepts & Ideas

Activities & Behaviors

Clinical Trials, Phase II as Topic

Living Beings

Pan troglodytes

Physiology

Platelet Activation

Disorders

Thrombocytopenia

Register to see full profile

Co-author Network

Register to see all co-authors

Publications

TOP 3
Dietmar Seiffert; Beth E Thomas; Jodi D Bradley; Deborah A Munzer; Maureen A Tchinnes; David M Kornhauser; Valerie A Cain; Tsushung Hua; Giora Z Feuerstein; David E Martin; Andrew M Stern
Effects of the glycoprotein IIb/IIIa antagonist Roxifiban on P-selectin expression, fibrinogen binding, and microaggregate formation in a phase I dose-finding study: no evidence for platelet activation during treatment with a glycoprotein IIb/IIIa antagonist.
Jeffrey T Billheimer; ira dicker; Richard Wynn; Jodi D Bradley; Debra Cromley; Helen E Godonis; Lisa C Grimminger; Bokang He; Cathy J Kieras; Donna L Pedicord; Susan M Spitz; Beth E Thomas; Nina I Zolotarjova; Mary A Gorko; Gregory F Hollis; Robert N Daly; Andrew M Stern; Dietmar Seiffert
Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated.
Donna L Pedicord; Beth E Thomas; Shaker A Mousa; ira dicker
Glycoprotein IIb/IIIa receptor antagonists inhibit the development of platelet procoagulant activity.

Register to see all publications

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Register to see more

Geonetwork of Beth Thomas (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Register to see more

All Publications

2003: Dietmar Seiffert; Beth E Thomas; Jodi D Bradley; Deborah A Munzer; Maureen A Tchinnes; David M Kornhauser; Valerie A Cain; Tsushung Hua; Giora Z Feuerstein; David E Martin; Andrew M Stern
Effects of the glycoprotein IIb/IIIa antagonist Roxifiban on P-selectin expression, fibrinogen binding, and microaggregate formation in a phase I dose-finding study: no evidence for platelet activation during treatment with a glycoprotein IIb/IIIa antagonist.
Platelets 2003;14(3):179-87.
2002: Jeffrey T Billheimer; ira dicker; Richard Wynn; Jodi D Bradley; Debra Cromley; Helen E Godonis; Lisa C Grimminger; Bokang He; Cathy J Kieras; Donna L Pedicord; Susan M Spitz; Beth E Thomas; Nina I Zolotarjova; Mary A Gorko; Gregory F Hollis; Robert N Daly; Andrew M Stern; Dietmar Seiffert
Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated.
Blood 2002;99(10):3540-6.
1998: Donna L Pedicord; Beth E Thomas; Shaker A Mousa; ira dicker
Glycoprotein IIb/IIIa receptor antagonists inhibit the development of platelet procoagulant activity.
Thrombosis research 1998;90(6):247-58.

Register to see more

Copyright © 2011 Elsevier Inc. All rights reserved.